14. Genotypes 2 and 3 Relapse and Non-Response

  1. Geoffrey W. McCaughan MBBS, PhD, FRACP2,3,
  2. John G. McHutchison MD4 and
  3. Jean-Michel Pawlotsky MD, PhD5,6
  1. Stella Martínez MD,
  2. Jose María Sánchez-Tapias MD, PhD and
  3. Xavier Forns MD, PhD

Published Online: 3 NOV 2011

DOI: 10.1002/9781444346343.ch14

Advanced Therapy for Hepatitis C

Advanced Therapy for Hepatitis C

How to Cite

Martínez, S., Sánchez-Tapias, J. M. and Forns, X. (2011) Genotypes 2 and 3 Relapse and Non-Response, in Advanced Therapy for Hepatitis C (eds G. W. McCaughan, J. G. McHutchison and J.-M. Pawlotsky), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444346343.ch14

Editor Information

  1. 2

    Centenary Research Institute, Sydney, NSW, Australia

  2. 3

    Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia

  3. 4

    Liver Disease Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA

  4. 5

    French National Reference Center for Viral Hepatitis B, C and delta, Créteil, France

  5. 6

    Department of Virology, Bacteriology, and Hygiene, INSERM U955, Hôpital Henri Mondor, Université Paris Est, Créteil, France

Author Information

  1. Liver Unit, Hospital Clinic, IDIBAPS and Ciberehd (Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas), Barcelona, Spain

Publication History

  1. Published Online: 3 NOV 2011
  2. Published Print: 24 NOV 2011

ISBN Information

Print ISBN: 9781405187459

Online ISBN: 9781444346343

SEARCH

Keywords:

  • genotypes 2 and 3 relapse, non-response;
  • chronic hepatitis C;
  • G2/G3 non-responders;
  • end of treatment (EOT) response;
  • relapse management;
  • drugs targeting HCV proteins;
  • Telaprevir;
  • viral load reductions

Summary

The efficacy of antiviral therapy in patients with chronic hepatitis C infected with genotypes 2 and 3 (G2/G3) is high; around 75–80% of these patients achieve a sustained virologic response with standard of care treatment. Because of the high rate of success, there has been little effort in trying to find out better strategies for non-responders. In fact, most of the clinical trials in G2/G3 infected patients in recent years have focused on shortening treatment regimens for those individuals with a good virologic profile. Thus, the information on antiviral therapy in G2/3 relapsers or non-responders is scarce. Most treatment failures in G2/G3 patients are due to relapse after on-treatment viral clearance. In these patients, re-treatment is usually a good strategy, particularly in those with a poor compliance or in those who underwent a short (<24 weeks) treatment regimen. In true non-responders, modification of some host factors (overweight, insulin resistance) and prolongation of therapy may also result in viral eradication.